Cargando…

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

SIMPLE SUMMARY: Several strategies have demonstrated the ability to improve the survival of patients with both metastatic and nonmetastatic prostate cancer. The old backbone of androgen-deprivation monotherapy has been disrupted in the hormone-sensitive setting, and several options have been introdu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cattrini, Carlo, España, Rodrigo, Mennitto, Alessia, Bersanelli, Melissa, Castro, Elena, Olmos, David, Lorente, David, Gennari, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467385/ https://www.ncbi.nlm.nih.gov/pubmed/34572748 http://dx.doi.org/10.3390/cancers13184522

Ejemplares similares

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2019)

Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights
por: Biello, Federica, et al.
Publicado: (2021)

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients
por: Cattrini, Carlo, et al.
Publicado: (2023)

Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
por: Lozano, Rebeca, et al.
Publicado: (2020)

Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer
por: Cattrini, Carlo, et al.
Publicado: (2020)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes
por: Cavo, Alessia, et al.
Publicado: (2018)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER
por: Antunac, Katarina, et al.
Publicado: (2022)

BRCA2 and Other DDR Genes in Prostate Cancer
por: Nombela, Paz, et al.
Publicado: (2019)

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study
por: Tommasi, Chiara, et al.
Publicado: (2023)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
por: Lorente, David, et al.
Publicado: (2016)

Advances and Highlights of miRNAs in Asthma: Biomarkers for Diagnosis and Treatment
por: Gil-Martínez, Marta, et al.
Publicado: (2023)

A hnRNP K–AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer
por: Capaia, Matteo, et al.
Publicado: (2018)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2020)

High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus
por: Navarro-Quiroz, Elkin, et al.
Publicado: (2016)

Advances in Prognostic Methylation Biomarkers for Prostate Cancer
por: Lam, Dilys, et al.
Publicado: (2020)

Biomarkers for Treatment Response in Advanced Prostate Cancer
por: Asif, Samia, et al.
Publicado: (2021)

SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
por: González del Alba, A., et al.
Publicado: (2021)

Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?
por: Barranco, Rosario, et al.
Publicado: (2020)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

COVID-19 and the newly rediscovered multidisciplinarity
por: Bersanelli, Melissa
Publicado: (2020)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
por: Shore, Neal D., et al.
Publicado: (2020)

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
por: Campora, Sara, et al.
Publicado: (2016)

Prognostic role of genetic biomarkers in clinical progression of prostate cancer
por: Alvarez-Cubero, Maria Jesus, et al.
Publicado: (2015)

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_afqd0jfpn27p069tuuc1j8lv36